XKRX
009420
Market cap1.67bUSD
Oct 08, Last price
44,000.00KRW
1D
-3.93%
1Q
-23.34%
Jan 2017
234.60%
Name
Hanall Biopharma Co Ltd
Chart & performance
P/E
—
P/S
14.42
EPS
—
Div yield, %
—
Shrs. gr., 5y
-0.53%
Rev. gr., 5y
11.86%
Revenues
155.18b
+11.69%
Net income
-5.56b
L+207.96%
CFO
-2.34b
L
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
HANALL BIOPHARMA Co., Ltd. engages in the manufacture and sale of synthetic drug and biopharmaceuticals. It offers products such as medicine for digestion, high blood pressure, cerebrovascular disease, myocardial infarction, anti-diabetics, antibiotics, gastrointestinal, bone structure, erectile dysfunction, hives, and other pharmaceutical products. The company was founded by Byeong-Tae Kim on November 20, 1973 and is headquartered in Daejeon, South Korea.
Key people
Chairman
Seung Won Jung
Co-Chief Executive Officer, Director
Seong Wun Kim
Assistant Managing Director
Seung Guk Park
Director · since 2024
Su Jin Park
Co-Chief Executive Officer, Director · since 2023
Heon Jung
Non-Executive Independent Director · since 2021
Han Ju Kim
Non-Executive Independent Director · since 2023
Cheol Heon Lee
Non-Executive Independent Director · since 2022
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||